SCHEMBL7122491

SCHEMBL7122491

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CC[C@H](CN2CCCC2)C1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.79
SRC P12931 9/20 0.79
FGFR1 P11362 8/20 0.79
MET P08581 7/20 0.79
PDGFRB P09619 7/20 0.79
LCK P06239 4/20 0.79
YES1 P07947 4/20 0.79
CDK2 P24941 2/20 0.79
PTK2B Q14289 2/20 0.79
MEN1 O00255 2/20 0.79
KMT2A Q03164 2/20 0.79
TDP1 Q9NUW8 2/20 0.79
EGFR P00533 2/20 0.79
PLK4 O00444 1/20 0.79
RIOK3 O14730 1/20 0.79
CASK O14936 1/20 0.79
GAK O14976 1/20 0.79
DCLK1 O15075 1/20 0.79
EPHB6 O15197 1/20 0.79
MAP3K13 O43283 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142239 0.97 KDR (0.80) KDRSRCFGFR1METPDGFRB
SCHEMBL140673 0.91 KDR (0.77) KDRSRCFGFR1METPDGFRB
SCHEMBL147361 0.91 KDR (0.72) KDRSRCFGFR1METPDGFRB
SCHEMBL144212 0.89 KDR (0.70) KDRSRCFGFR1METPDGFRB
SCHEMBL141560 0.89 KDR (0.70) KDRSRCFGFR1METPDGFRB
SCHEMBL144160 0.89 KDR (0.73) KDRSRCFGFR1METPDGFRB
SCHEMBL141372 0.89 KDR (0.68) KDRSRCFGFR1METPDGFRB
SCHEMBL144899 0.89 KDR (0.73) KDRSRCFGFR1METPDGFRB
Pha-665752 SCHEMBL140412 0.88 KDR (1.00) KDRSRCFGFR1METPDGFRB
Pha-665752 SCHEMBL93657 0.88 KDR (1.00) KDRSRCFGFR1METPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885SRC 75/4885FGFR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.